<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Overview of the acute management of tachyarrhythmias</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Overview of the acute management of tachyarrhythmias</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Overview of the acute management of tachyarrhythmias</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jordan M Prutkin, MD, MHA, MHS</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">James Hoekstra, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Hugh Calkins, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Todd F Dardas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 31, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Tachyarrhythmias, defined as abnormal heart rhythms with a ventricular rate of 100 or more beats per minute, are frequently symptomatic and often result in patients seeking care at their provider's office or the emergency department. Signs and symptoms related to the tachyarrhythmia may include shock, hypotension, heart failure, shortness of breath, chest pain, acute myocardial infarction, palpitations, and/or decreased level of consciousness. An overview of the management of these various arrhythmias will be presented here. More complete reviews of the individual arrhythmias are discussed separately.</p><p class="headingAnchor" id="H1040743"><span class="h1">INITIAL DIAGNOSTIC AND TREATMENT DECISIONS</span><span class="headingEndMark"> — </span>In patients who present with a symptomatic tachyarrhythmia, a 12-lead electrocardiogram (ECG) should be obtained while a brief initial assessment of the patient's overall clinical assessment is performed. If the patient is hemodynamically unstable, it may be preferable to obtain only a rhythm strip prior to urgent cardioversion and not wait for a 12-lead ECG. The information acquired from these initial assessments is crucial for subsequent management of the patient.</p><p class="headingAnchor" id="H1040751"><span class="h2">Is the patient clinically (or hemodynamically) unstable?</span><span class="headingEndMark"> — </span>The most important clinical determination in a patient presenting with a tachyarrhythmia is whether or not the patient is experiencing signs and symptoms related to the rapid heart rate. These can include hypotension, shortness of breath, chest pain suggestive of coronary ischemia, shock, and/or decreased level of consciousness.</p><p>Determining whether a patient's symptoms are related to the tachycardia depends upon several factors, including age and the presence of underlying cardiac disease.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hemodynamically unstable and not sinus rhythm</strong> – If a patient has clinically significant hemodynamic instability potentially due to the tachyarrhythmia, an attempt should be made as quickly as possible to determine whether the rhythm is sinus tachycardia  (<a class="graphic graphic_algorithm graphicRef109811" href="/d/graphic/109811.html" rel="external">algorithm 1</a>). If the rhythm is not sinus tachycardia, or if there is any doubt that the rhythm is sinus tachycardia, <strong>urgent conversion </strong>to sinus rhythm is recommended. (See  <a class="medical medical_review" href="/d/html/943.html" rel="external">"Narrow QRS complex tachycardias: Clinical manifestations, diagnosis, and evaluation", section on 'Similar to sinus rhythm'</a> and  <a class="medical medical_review" href="/d/html/975.html" rel="external">"Basic principles and technique of external electrical cardioversion and defibrillation"</a> and  <a class="medical medical_review" href="/d/html/920.html" rel="external">"Wide QRS complex tachycardias: Approach to the diagnosis", section on 'Assessment of hemodynamic stability'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hemodynamically stable</strong> – If the patient is not experiencing hemodynamic instability, a nonemergent approach to the diagnosis of the patient's rhythm can be undertaken [<a href="#rid1">1-3</a>]. A close examination of the 12-lead ECG should permit the correct identification of the arrhythmia in 80 percent of cases [<a href="#rid4">4</a>]. (See <a class="local">'Is the QRS complex narrow or wide? Regular or irregular?'</a> below and  <a class="medical medical_review" href="/d/html/943.html" rel="external">"Narrow QRS complex tachycardias: Clinical manifestations, diagnosis, and evaluation", section on 'Evaluation'</a> and  <a class="medical medical_review" href="/d/html/920.html" rel="external">"Wide QRS complex tachycardias: Approach to the diagnosis", section on 'Evaluation of the electrocardiogram'</a>.)</p><p></p><p class="headingAnchor" id="H1040758"><span class="h2">Is the QRS complex narrow or wide? Regular or irregular?</span><span class="headingEndMark"> — </span>Treatment of any tachyarrhythmia depends on a variety of clinical factors. However, most treatment decisions are made based on the width, morphology, and regularity of the QRS complex  (<a class="graphic graphic_algorithm graphicRef117571" href="/d/graphic/117571.html" rel="external">algorithm 2</a>). In most patients, the differentiation between narrow and wide QRS complex tachyarrhythmias requires only a surface ECG.</p><p class="bulletIndent1"><span class="glyph">●</span>Narrow QRS complex tachyarrhythmias have a QRS complex &lt;120 milliseconds in duration</p><p class="bulletIndent1"><span class="glyph">●</span>Wide QRS complex tachyarrhythmias have a QRS complex ≥120 milliseconds in duration</p><p></p><p>The various types of narrow and wide QRS complex tachyarrhythmias are discussed below. (See <a class="local">'Narrow QRS complex tachyarrhythmias'</a> below and <a class="local">'Wide QRS complex tachyarrhythmias'</a> below.)</p><p class="headingAnchor" id="H1041109"><span class="h1">NARROW QRS COMPLEX TACHYARRHYTHMIAS</span><span class="headingEndMark"> — </span>Discussion of the treatment of narrow QRS complex tachycardias will be divided into those with a regular ventricular response and those with an irregular ventricular response  (<a class="graphic graphic_algorithm graphicRef76920" href="/d/graphic/76920.html" rel="external">algorithm 3</a> and <a class="graphic graphic_algorithm graphicRef109811" href="/d/graphic/109811.html" rel="external">algorithm 1</a>).</p><p class="headingAnchor" id="H1041227"><span class="h2">Regular narrow QRS complex tachyarrhythmias</span><span class="headingEndMark"> — </span>The regular narrow QRS complex tachycardias include  (<a class="graphic graphic_algorithm graphicRef117571" href="/d/graphic/117571.html" rel="external">algorithm 2</a>) [<a href="#rid3">3</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Sinus tachycardia (see  <a class="medical medical_review" href="/d/html/1074.html" rel="external">"Sinus tachycardia: Evaluation and management"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Inappropriate sinus tachycardia (see  <a class="medical medical_review" href="/d/html/1074.html" rel="external">"Sinus tachycardia: Evaluation and management", section on 'Inappropriate sinus tachycardia'</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Sinoatrial nodal reentrant tachycardia (SANRT) (see  <a class="medical medical_review" href="/d/html/918.html" rel="external">"Sinoatrial nodal reentrant tachycardia (SANRT)"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Atrioventricular nodal reentrant tachycardia (AVNRT) (see  <a class="medical medical_review" href="/d/html/902.html" rel="external">"Atrioventricular nodal reentrant tachycardia"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Atrioventricular reentrant (or reciprocating) tachycardia (AVRT) (see  <a class="medical medical_review" href="/d/html/976.html" rel="external">"Atrioventricular reentrant tachycardia (AVRT) associated with an accessory pathway"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Atrial tachycardia (AT) (see  <a class="medical medical_review" href="/d/html/900.html" rel="external">"Focal atrial tachycardia"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Atrial flutter (see  <a class="medical medical_review" href="/d/html/1048.html" rel="external">"Overview of atrial flutter"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Intraatrial reentrant tachycardia (IART) (see  <a class="medical medical_review" href="/d/html/937.html" rel="external">"Intraatrial reentrant tachycardia"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Junctional ectopic tachycardia </p><p class="bulletIndent1"><span class="glyph">●</span>Nonparoxysmal junctional tachycardia</p><p></p><p>Because the vast majority of regular narrow QRS complex tachycardias are due to sinus tachycardia, AVNRT, AVRT, AT, and atrial flutter, these conditions will be presented here. Discussions regarding the treatment of the other less common types of regular narrow QRS complex tachycardias are presented separately. (See  <a class="medical medical_review" href="/d/html/1074.html" rel="external">"Sinus tachycardia: Evaluation and management", section on 'Inappropriate sinus tachycardia'</a> and  <a class="medical medical_review" href="/d/html/918.html" rel="external">"Sinoatrial nodal reentrant tachycardia (SANRT)", section on 'Treatment'</a> and  <a class="medical medical_review" href="/d/html/937.html" rel="external">"Intraatrial reentrant tachycardia", section on 'Treatment'</a> and  <a class="medical medical_review" href="/d/html/996.html" rel="external">"Treatment of arrhythmias associated with the Wolff-Parkinson-White syndrome", section on 'Permanent junctional reciprocating tachycardia'</a>.)</p><p class="headingAnchor" id="H30456082"><span class="h3">Sinus tachycardia</span><span class="headingEndMark"> — </span>The most common tachycardia is sinus tachycardia. If it is certain that the patient's rhythm is sinus tachycardia and clinically significant cardiac symptoms are present, management should be focused on the underlying disorder and on treating any contributing cause of the rapid heart rate (eg, coronary ischemia, pulmonary embolism, respiratory or cardiac failure, hypovolemia, anemia, hyperthyroidism, fever, pain, or anxiety). This may include volume replacement or diuresis, antibiotics, anti-pyretics, oxygen, pain control, or other treatments as appropriate. In patients with sinus tachycardia and certain forms of heart disease, such as coronary disease or aortic stenosis, treatment may need to be directed at the heart rate itself. In such cases, cautious use of an intravenous beta blocker is appropriate. (See  <a class="medical medical_review" href="/d/html/1074.html" rel="external">"Sinus tachycardia: Evaluation and management"</a> and  <a class="medical medical_review" href="/d/html/96.html" rel="external">"Acute myocardial infarction: Role of beta blocker therapy"</a> and  <a class="medical medical_review" href="/d/html/8130.html" rel="external">"Medical management of symptomatic aortic stenosis"</a>.)</p><p class="headingAnchor" id="H30456175"><span class="h3">Atrioventricular nodal reentrant tachycardia (AVNRT)</span><span class="headingEndMark"> — </span>Patients with AVNRT associated with hemodynamic compromise or severe symptoms due to the tachycardia (eg, angina, hypotension, or heart failure) require rapid termination of the arrhythmia. (See  <a class="medical medical_review" href="/d/html/902.html" rel="external">"Atrioventricular nodal reentrant tachycardia", section on 'Initial management'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>For patients with AVNRT who are hemodynamically unstable related to their arrhythmia, we recommend immediate DC cardioversion. Consideration for using vagal maneuvers (Valsalva maneuver or carotid sinus massage) is also reasonable if it does not delay cardioversion. (See  <a class="medical medical_review" href="/d/html/1034.html" rel="external">"Vagal maneuvers"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with AVNRT associated with severe symptoms due to the tachycardia (eg, angina, hypotension, heart failure, or mental status changes) in whom intravenous access is available, we suggest an initial attempt at termination with <a class="drug drug_general" data-topicid="9359" href="/d/drug information/9359.html" rel="external">adenosine</a>  (<a class="graphic graphic_algorithm graphicRef141417" href="/d/graphic/141417.html" rel="external">algorithm 4</a>) rather than cardioversion. If adenosine cannot be administered or is ineffective, patients should undergo immediate DC cardioversion.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with AVNRT that is not associated with severe symptoms or hemodynamic collapse, including patients without symptoms, we suggest the following sequential approach to acute termination:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Vagal maneuvers (see  <a class="medical medical_review" href="/d/html/1034.html" rel="external">"Vagal maneuvers"</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>IV <a class="drug drug_general" data-topicid="9359" href="/d/drug information/9359.html" rel="external">adenosine</a>  (<a class="graphic graphic_algorithm graphicRef141417" href="/d/graphic/141417.html" rel="external">algorithm 4</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>IV non-dihydropyridine calcium channel blocker or an IV beta blocker</p><p></p><p class="headingAnchor" id="H30456182"><span class="h3">Atrioventricular reentrant tachycardia (AVRT)</span><span class="headingEndMark"> — </span>Patients with arrhythmias that may be caused or complicated by the presence of an accessory pathway (ie, orthodromic AVRT, antidromic AVRT, preexcited atrial fibrillation/flutter) should have a prompt initial assessment of hemodynamic status. The management of AVRT depends on the stability of the patient and whether the mechanism of tachycardia is known or unknown. The approach to management of orthodromic AVRT, which most commonly presents with narrow QRS complexes, is discussed separately. (See  <a class="medical medical_review" href="/d/html/996.html" rel="external">"Treatment of arrhythmias associated with the Wolff-Parkinson-White syndrome", section on 'Orthodromic AVRT'</a>.)</p><p class="headingAnchor" id="H30456218"><span class="h3">Atrial tachycardia</span><span class="headingEndMark"> — </span>Focal atrial tachycardias (AT), usually paroxysmal and self-limited, arise from a single site or area of microreentry or enhanced automaticity outside of the sinus node. (See  <a class="medical medical_review" href="/d/html/900.html" rel="external">"Focal atrial tachycardia", section on 'Acute treatment'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>For patients with AT who are felt to be hemodynamically unstable related to their arrhythmia, we recommend immediate DC cardioversion.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For a hemodynamically stable patient with symptomatic AT, we suggest acute treatment with an oral or intravenous beta blocker or non-dihydropyridine calcium channel blocker (ie, <a class="drug drug_general" data-topicid="9365" href="/d/drug information/9365.html" rel="external">diltiazem</a> or <a class="drug drug_general" data-topicid="10043" href="/d/drug information/10043.html" rel="external">verapamil</a>). Such treatment may slow the ventricular response and/or terminate the arrhythmia. Intravenous <a class="drug drug_general" data-topicid="8595" href="/d/drug information/8595.html" rel="external">amiodarone</a> is an acceptable alternative that may be preferred in a patient with borderline hypotension as amiodarone may slow the rate or convert the rhythm back to normal sinus.</p><p></p><p class="headingAnchor" id="H540969608"><span class="h3">Atrial flutter</span><span class="headingEndMark"> — </span>Atrial flutter usually presents as a regular narrow complex tachycardia, though it occasionally may have an irregular ventricular response. Atrial flutter should always be considered high on the differential diagnosis when a patient presents with a regular narrow complex tachycardia with a ventricular response of approximately 150 beats per minute. As with atrial fibrillation, the early steps in the management of a patient with new onset atrial flutter involve an assessment of the need for cardioversion, ventricular rate slowing therapy, and antithrombotic therapy. Our initial approach to the management of patients with atrial flutter is the same as our approach for atrial fibrillation. (See <a class="local">'Atrial fibrillation'</a> below.)</p><p class="headingAnchor" id="H30456299"><span class="h2">Irregular narrow QRS complex tachyarrhythmias</span><span class="headingEndMark"> — </span>The irregular narrow QRS complex tachycardias include  (<a class="graphic graphic_algorithm graphicRef117571" href="/d/graphic/117571.html" rel="external">algorithm 2</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Atrial fibrillation (AF) (see  <a class="medical medical_review" href="/d/html/1022.html" rel="external">"Atrial fibrillation: Overview and management of new-onset atrial fibrillation"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Atrial flutter with variable conduction (see  <a class="medical medical_review" href="/d/html/1048.html" rel="external">"Overview of atrial flutter"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Focal atrial tachycardia with variable conduction (see  <a class="medical medical_review" href="/d/html/900.html" rel="external">"Focal atrial tachycardia"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Multifocal atrial tachycardia (MAT) (see  <a class="medical medical_review" href="/d/html/901.html" rel="external">"Multifocal atrial tachycardia"</a>)</p><p></p><p class="headingAnchor" id="H8336616"><span class="h3">Atrial fibrillation</span><span class="headingEndMark"> — </span>Most patients with new onset (ie, first detected or diagnosed) AF with a rapid rate present with symptoms related to the arrhythmia. Except for embolization, the symptoms associated with new onset AF are primarily due to a rapid and/or irregular ventricular response. The early steps in the management of a patient with new onset rapid AF involve an assessment of the need for cardioversion, ventricular rate slowing therapy, and antithrombotic therapy. (See  <a class="medical medical_review" href="/d/html/1022.html" rel="external">"Atrial fibrillation: Overview and management of new-onset atrial fibrillation"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Urgent or emergent cardioversion should be considered for patients with active ischemia, significant hypotension, severe heart failure, or the presence of a preexcitation syndrome associated with rapid conduction using the accessory pathway. (See <a class="local">'Atrioventricular reentrant tachycardia (AVRT)'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For all patients who do not require urgent or emergent cardioversion, we recommend rate control to improve symptoms and to reduce the risk of tachycardia-mediated cardiomyopathy. We believe a goal of less than 110 beats per minute is reasonable for an asymptomatic patient with a normal ejection fraction. Beta blockers and non-dihydropyridine calcium channel blockers are preferred as first-line agents in most patients, and <a class="drug drug_general" data-topicid="9360" href="/d/drug information/9360.html" rel="external">digoxin</a> should only rarely be used. Intravenous preparations are preferred to oral preparations when rapid control of rate is necessary.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with AF less than 48 hours in duration in whom cardioversion is planned, the use of antithrombotic therapy pre-cardioversion to reduce the risk of embolization can be considered.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with AF longer than 48 hours in duration (or of unknown duration), we recommend four weeks of therapeutic oral anticoagulation prior to cardioversion, as opposed to immediate cardioversion. Transesophageal echocardiography-based (TEE) screening for the presence of atrial thrombi is recommended if cardioversion is desired earlier than four weeks. Anticoagulation must be continued for a minimum of four weeks after cardioversion. Whether long-term anticoagulation is indicated depends on assessment of the patient's thromboembolic risk profile. (See  <a class="medical medical_review" href="/d/html/128998.html" rel="external">"Atrial fibrillation in adults: Selection of candidates for anticoagulation"</a>.)</p><p></p><p class="headingAnchor" id="H636766958"><span class="h3">Atrial flutter</span><span class="headingEndMark"> — </span>As with atrial fibrillation, the early steps in the management of a patient with new onset atrial flutter involve an assessment of the need for cardioversion, ventricular rate slowing therapy, and antithrombotic therapy. Our initial approach to the management of patients with atrial flutter is the same as our approach for atrial fibrillation. (See <a class="local">'Atrial fibrillation'</a> above.)</p><p class="headingAnchor" id="H8336630"><span class="h3">Multifocal atrial tachycardia</span><span class="headingEndMark"> — </span>Multifocal atrial tachycardia (MAT) is an arrhythmia with organized atrial activity yielding P waves with three or more different morphologies. MAT is commonly associated with significant underlying pulmonary or cardiac illness. (See  <a class="medical medical_review" href="/d/html/901.html" rel="external">"Multifocal atrial tachycardia", section on 'Treatment'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Most episodes of MAT do not precipitate hemodynamic compromise or limiting symptoms. Thus, therapy in patients with MAT should be aimed at the inciting underlying disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with MAT and associated hypokalemia or hypomagnesemia should undergo electrolyte repletion prior to the initiation of additional medical therapy for MAT.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Medical therapy for MAT is indicated only if MAT causes a sustained rapid ventricular response that causes or worsens myocardial ischemia, heart failure, peripheral perfusion, or oxygenation. Options for medical therapy for patients with symptomatic MAT requiring ventricular rate control include non-dihydropyridine calcium channel blockers and beta blockers. For patients without heart failure or bronchospasm, we suggest initial therapy with a beta blocker, usually <a class="drug drug_general" data-topicid="9645" href="/d/drug information/9645.html" rel="external">metoprolol</a>, before calcium channel blockers. Conversely, for patients with severe bronchospasm, we suggest initial therapy with a non-dihydropyridine calcium channel blocker, usually <a class="drug drug_general" data-topicid="10043" href="/d/drug information/10043.html" rel="external">verapamil</a>, rather than a beta blocker. Beta blockers may be used cautiously in patients with stable heart failure. Rate control therapy is typically unsuccessful, however, without treating the underlying disorder.</p><p></p><p class="headingAnchor" id="H14"><span class="h1">WIDE QRS COMPLEX TACHYARRHYTHMIAS</span><span class="headingEndMark"> — </span>Discussion of the treatment of wide QRS complex tachycardias, similar to narrow QRS complex tachycardias, can be divided into those with a regular or irregular ventricular rate.</p><p class="headingAnchor" id="H540969796"><span class="h2">Regular wide QRS complex tachyarrhythmias</span><span class="headingEndMark"> — </span>The regular wide QRS complex tachycardias include  (<a class="graphic graphic_algorithm graphicRef117571" href="/d/graphic/117571.html" rel="external">algorithm 2</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Monomorphic ventricular tachycardia (VT). (See  <a class="medical medical_review" href="/d/html/1040.html" rel="external">"Sustained monomorphic ventricular tachycardia in patients with structural heart disease: Treatment and prognosis"</a> and  <a class="medical medical_review" href="/d/html/965.html" rel="external">"Ventricular tachycardia in the absence of apparent structural heart disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Supraventricular tachycardia with aberrant conduction, underlying conduction delay, conduction over an accessory pathway (eg, AVNRT with right bundle branch block), or a paced ventricular response.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Supraventricular tachycardia in a patient on certain antiarrhythmic medications or with significant electrolyte abnormalities.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Antidromic AVRT.</p><p></p><p>The most concerning potential cause of a wide QRS complex tachycardia is VT, and, in the majority of patients, the arrhythmia should be assumed to be VT until proven otherwise.</p><p>Immediate assessment of patient stability takes precedence over any further diagnostic evaluation. (See  <a class="medical medical_review" href="/d/html/920.html" rel="external">"Wide QRS complex tachycardias: Approach to the diagnosis", section on 'Summary and recommendations'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>A patient who is unresponsive or pulseless should be treated according to standard advance cardiac life support (ACLS) algorithms  (<a class="graphic graphic_algorithm graphicRef129983" href="/d/graphic/129983.html" rel="external">algorithm 5</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a patient who is unstable but conscious, we recommend immediate synchronized cardioversion with appropriate sedation when possible.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a stable patient, a focused diagnostic evaluation may proceed to determine the etiology of the arrhythmia and guide specific therapy.</p><p></p><p class="headingAnchor" id="H8337612"><span class="h3">Ventricular tachycardia</span><span class="headingEndMark"> — </span>In stable patients with known or presumed VT, we recommend the following approach (see  <a class="medical medical_review" href="/d/html/920.html" rel="external">"Wide QRS complex tachycardias: Approach to the diagnosis", section on 'Summary and recommendations'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>We recommend synchronized external cardioversion, following appropriate sedation, as the initial therapy for most patients with stable VT. If the patient has an implantable cardioverter-defibrillator, it may be possible to terminate the arrhythmia by antitachycardia pacing prior to an attempted cardioversion.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients with refractory or recurrent wide complex tachycardia (WCT), we suggest an intravenous class I or III antiarrhythmic drug  (<a class="graphic graphic_table graphicRef120433" href="/d/graphic/120433.html" rel="external">table 1</a>), such as <a class="drug drug_general" data-topicid="8595" href="/d/drug information/8595.html" rel="external">amiodarone</a>, <a class="drug drug_general" data-topicid="9558" href="/d/drug information/9558.html" rel="external">lidocaine</a>, or <a class="drug drug_general" data-topicid="9813" href="/d/drug information/9813.html" rel="external">procainamide</a>  (<a class="graphic graphic_algorithm graphicRef141920" href="/d/graphic/141920.html" rel="external">algorithm 6</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In selected patients known to have one of the syndromes of VT in the setting of a structurally normal heart, we suggest calcium channel blockers or beta blockers be used for arrhythmia termination or suppression. However, the decision to use these drugs in this setting should be made in consultation with a cardiologist experienced in arrhythmia management.</p><p></p><p class="headingAnchor" id="H8337725"><span class="h3">Supraventricular tachycardia with aberrant conduction</span><span class="headingEndMark"> — </span>The narrow complex supraventricular tachycardia (SVT) rhythms may present with a wide complex in the setting of aberrant conduction or conduction over an accessory pathway (not including AVRT).</p><p class="bulletIndent1"><span class="glyph">●</span>In stable patients with a WCT that is <strong>known</strong> to be an SVT, initial management is similar to that of an SVT with a narrow QRS complex. A continuous rhythm strip should be obtained during any intervention that is intended to slow or terminate the arrhythmia. (See <a class="local">'Regular narrow QRS complex tachyarrhythmias'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For AVNRT or AVRT, or an SVT in which the specific arrhythmia is <strong>unknown</strong>, we suggest the following sequence of interventions in order to terminate the arrhythmia or to slow ventricular response and facilitate diagnosis in stable patients:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Vagotonic maneuvers (eg, Valsalva or carotid sinus pressure)</p><p class="bulletIndent2"><span class="glyph">•</span>Intravenous <a class="drug drug_general" data-topicid="9359" href="/d/drug information/9359.html" rel="external">adenosine</a>  (<a class="graphic graphic_algorithm graphicRef141417" href="/d/graphic/141417.html" rel="external">algorithm 4</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Intravenous calcium channel blockers or beta blockers</p><p class="bulletIndent2"><span class="glyph">•</span>Cardioversion in selected persistent cases, or if the patient is unstable</p><p></p><p class="headingAnchor" id="H540969885"><span class="h3">Supraventricular tachycardia with a pacemaker</span><span class="headingEndMark"> — </span>Regular wide QRS complex tachycardias in patients with a pacemaker may be due to tracking of one of the typical supraventricular tachycardias (eg, sinus tachycardia, atrial flutter, etc) or may be due to pacemaker-mediated tachycardia (PMT, also referred to endless loop tachycardia [ELT]). (See  <a class="medical medical_review" href="/d/html/1037.html" rel="external">"Unexpected rhythms with normally functioning dual-chamber pacing systems", section on 'Pacemaker-mediated tachycardia'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>In patients with tracking of a native supraventricular tachyarrhythmia, the pacemaker usually should automatically mode switch to a non-tracking mode. If it does not, placing a magnet on the pacemaker will lead to asynchronous pacing at a fixed and lower rate, and the pacemaker settings can be adjusted to prevent rapid pacing.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If the rhythm is due to PMT, retrograde conduction from the ventricle to the atrium is sensed by the pacemaker and serves as a trigger to pace the ventricle, which again conducts back to the atrium and perpetuates the tachycardia. Placing a magnet on the pacemaker leads to asynchronous pacing and will stop the tachycardia. Most pacemakers have algorithms to prevent or treat PMT, but pacemaker settings can usually be reprogrammed if they are ineffective.</p><p></p><p class="headingAnchor" id="H540969891"><span class="h3">Antidromic AVRT</span><span class="headingEndMark"> — </span>For patients with acute symptomatic antidromic AVRT (regular and wide QRS complexes) who are hemodynamically stable, the approach to acute management is discussed separately. (See  <a class="medical medical_review" href="/d/html/996.html" rel="external">"Treatment of arrhythmias associated with the Wolff-Parkinson-White syndrome", section on 'Antidromic AVRT'</a>.)</p><p class="headingAnchor" id="H540969897"><span class="h2">Irregular wide QRS complex tachyarrhythmias</span><span class="headingEndMark"> — </span>The irregular wide QRS complex tachycardias include  (<a class="graphic graphic_algorithm graphicRef117571" href="/d/graphic/117571.html" rel="external">algorithm 2</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Polymorphic VT, including torsades de pointes. (See  <a class="medical medical_review" href="/d/html/1043.html" rel="external">"Acquired long QT syndrome: Definitions, pathophysiology, and causes"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Irregular narrow complex tachycardias with aberrant conduction, antegrade conduction over an accessory pathway (eg, preexcited AF), or underlying conduction delay (eg, AF with right bundle branch block).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Ventricular fibrillation.</p><p></p><p class="headingAnchor" id="H16"><span class="h3">Polymorphic ventricular tachycardia</span><span class="headingEndMark"> — </span>Polymorphic ventricular tachycardia (VT) is defined as an unstable rhythm with a continuously varying QRS complex morphology in any recorded electrocardiographic (ECG) lead. Polymorphic VT is generally a rapid and hemodynamically unstable rhythm, and urgent defibrillation is usually necessary. In addition to immediate defibrillation, further therapy is intended to treat underlying disorders and to prevent recurrences. The specific approach depends upon whether or not the QT interval on the baseline ECG is prolonged. Polymorphic VT that occurs in the setting of QT prolongation in sinus rhythm is considered as a distinct arrhythmia, called torsades de pointes. (See  <a class="medical medical_review" href="/d/html/1043.html" rel="external">"Acquired long QT syndrome: Definitions, pathophysiology, and causes"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Prompt defibrillation is indicated in patients with hemodynamically unstable torsades de pointes.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the conscious patient with recurrent episodes of torsades de pointes:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Intravenous <a class="drug drug_general" data-topicid="9585" href="/d/drug information/9585.html" rel="external">magnesium sulfate</a> (initial dose of 1 to 2 grams IV over 15 minutes, may be followed by an infusion) is first-line therapy, as it is highly effective for both treatment and prevention of recurrence of long QT-related ventricular ectopic beats that trigger torsades de pointes. The benefit is seen even in patients with normal serum magnesium concentrations at baseline.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Temporary transvenous overdrive pacing (atrial or ventricular) at about 100 beats per minute is generally reserved for patients who do not respond to intravenous magnesium.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In those with congenital long QT syndrome, beta blockers may be used to reduce the frequency of premature ventricular contractions and shorten the QT interval.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with polymorphic VT triggered by pauses or bradycardia, <a class="drug drug_general" data-topicid="8578" href="/d/drug information/8578.html" rel="external">isoproterenol</a> (initial dose 0.05 to 0.1 mcg/kg per minute in children and 2 mcg/minute in adults, then titrated to achieve a heart rate of 100 beats per minute) can be used as a temporizing measure to achieve a heart rate of 100 beats per minute prior to pacing.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with polymorphic VT and a normal baseline QT interval, the most likely cause is myocardial ischemia. Treatments may include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Prompt defibrillation in the hemodynamically unstable patient.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Beta-blockers if blood pressure tolerates. <a class="drug drug_general" data-topicid="9645" href="/d/drug information/9645.html" rel="external">Metoprolol</a> 5 mg intravenously every five minutes, to a total of 15 mg, may be given.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>IV <a class="drug drug_general" data-topicid="8595" href="/d/drug information/8595.html" rel="external">amiodarone</a> may prevent a recurrent episode.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Urgent coronary angiography and possible revascularization.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Short-term mechanical circulatory support.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Magnesium is less likely to be effective for polymorphic VT if the baseline QT interval is normal.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If the polymorphic VT is due to catecholaminergic polymorphic ventricular tachycardia (CPVT), beta blockers should be used. If it is due to Brugada syndrome, <a class="drug drug_general" data-topicid="8578" href="/d/drug information/8578.html" rel="external">isoproterenol</a> should be initiated. (See  <a class="medical medical_review" href="/d/html/916.html" rel="external">"Catecholaminergic polymorphic ventricular tachycardia", section on 'Acute management'</a> and  <a class="medical medical_review" href="/d/html/106760.html" rel="external">"Brugada syndrome or pattern: Management and approach to screening of relatives"</a>.)</p><p></p><p class="headingAnchor" id="H1907264395"><span class="h3">Preexcited atrial fibrillation</span><span class="headingEndMark"> — </span>Patients with preexcited atrial fibrillation are typically treated with agents that minimize the risk of rapid conduction of atrial fibrillation or atrial flutter directly to the ventricle. The approach to patients with an accessory pathway and atrial fibrillation or flutter is discussed separately. (See  <a class="medical medical_review" href="/d/html/996.html" rel="external">"Treatment of arrhythmias associated with the Wolff-Parkinson-White syndrome", section on 'Atrial fibrillation with preexcitation'</a>.)</p><p class="headingAnchor" id="H1534999366"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/112091.html" rel="external">"Society guideline links: Atrial fibrillation"</a> and  <a class="medical medical_society_guidelines" href="/d/html/112260.html" rel="external">"Society guideline links: Arrhythmias in adults"</a> and  <a class="medical medical_society_guidelines" href="/d/html/115586.html" rel="external">"Society guideline links: Ventricular arrhythmias"</a> and  <a class="medical medical_society_guidelines" href="/d/html/117075.html" rel="external">"Society guideline links: Basic and advanced cardiac life support in adults"</a> and  <a class="medical medical_society_guidelines" href="/d/html/116931.html" rel="external">"Society guideline links: Supraventricular arrhythmias"</a>.)</p><p class="headingAnchor" id="H29640071"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/16998.html" rel="external">"Patient education: Tachycardia (The Basics)"</a> and  <a class="medical medical_basics" href="/d/html/17131.html" rel="external">"Patient education: Ventricular tachycardia (The Basics)"</a> and  <a class="medical medical_basics" href="/d/html/86463.html" rel="external">"Patient education: Supraventricular tachycardia (SVT) (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H5231327"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial diagnostic and treatment decisions</strong> – In patients who present with a symptomatic tachyarrhythmia, a 12-lead ECG should be obtained while a brief initial assessment of the patient's overall clinical assessment is performed. If the patient is hemodynamically unstable, it may be preferable to obtain only a rhythm strip prior to urgent cardioversion and not wait for a 12-lead ECG. The information acquired from these initial assessments is crucial for subsequent management of the patient (see <a class="local">'Initial diagnostic and treatment decisions'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Narrow QRS complex tachycardias</strong> – If the QRS complex is narrow  (<a class="graphic graphic_algorithm graphicRef117571" href="/d/graphic/117571.html" rel="external">algorithm 2</a>), the approach to acute management is based on whether the patient is stable  (<a class="graphic graphic_algorithm graphicRef76920" href="/d/graphic/76920.html" rel="external">algorithm 3</a>) or unstable  (<a class="graphic graphic_algorithm graphicRef109811" href="/d/graphic/109811.html" rel="external">algorithm 1</a>). (See <a class="local">'Narrow QRS complex tachyarrhythmias'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Wide QRS complex tachycardias</strong> – If the QRS complex is wide  (<a class="graphic graphic_algorithm graphicRef117571" href="/d/graphic/117571.html" rel="external">algorithm 2</a>), the approach to acute management is based on whether the patient is stable or unstable; pulseless patients should be treated according to the adult cardiac life support algorithm  (<a class="graphic graphic_algorithm graphicRef129983" href="/d/graphic/129983.html" rel="external">algorithm 5</a>). (See <a class="local">'Wide QRS complex tachyarrhythmias'</a> above.)</p><p></p><p class="headingAnchor" id="H540970087"><span class="h1">ACKNOWLEDGMENTS</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Philip Podrid, MD, FACC, and Leonard Ganz, MD, FHRS, FACC, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Link MS. Clinical practice. Evaluation and initial treatment of supraventricular tachycardia. N Engl J Med 2012; 367:1438.</a></li><li><a class="nounderline abstract_t">Page RL, Joglar JA, Caldwell MA, et al. 2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2016; 67:e27.</a></li><li><a class="nounderline abstract_t">Brugada J, Katritsis DG, Arbelo E, et al. 2019 ESC Guidelines for the management of patients with supraventricular tachycardiaThe Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC). Eur Heart J 2020; 41:655.</a></li><li><a class="nounderline abstract_t">Kalbfleisch SJ, el-Atassi R, Calkins H, et al. Differentiation of paroxysmal narrow QRS complex tachycardias using the 12-lead electrocardiogram. J Am Coll Cardiol 1993; 21:85.</a></li></ol></div><div id="topicVersionRevision">Topic 936 Version 45.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23050527" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Clinical practice. Evaluation and initial treatment of supraventricular tachycardia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26409259" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : 2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31504425" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : 2019 ESC Guidelines for the management of patients with supraventricular tachycardiaThe Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8417081" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Differentiation of paroxysmal narrow QRS complex tachycardias using the 12-lead electrocardiogram.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
